Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Overview
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Companies Involved in Therapeutics Development
Hadasit Medical Research Services and Development Ltd
Innovate Biopharmacueticals Inc
Oasis Pharmaceuticals LLC
PeptiDream Inc
Sosei Heptares
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Drug Profiles
GB-88 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Antagonize PAR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-2pal18S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PZ-235 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize PAR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Dormant Products
Proteise Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Product Development Milestones
Featured News & Press Releases
Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
Jun 24, 2019: Innovate Biopharmaceuticals expands its magement team with the addition of Ed Sitar as Its Chief Fincial Officer
Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
May 20, 2019: Innovate Biopharmaceuticals announces presentation of three posters focusing on the molecular biology and pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego
Apr 29, 2019: Innovate Biopharmaceuticals shows Larazotide is the first drug, with its novel mechanism of action of re-normalizing the intestil barrier, to demonstrate improvements in validated SH biomarkers and endpoints in synergy with obeticholic acid, an FXR ag
Apr 11, 2019: Innovate Biopharmaceuticals presents oral poster at European Association for the Study of the Liver (EASL) demonstrating positive effect of larazotide on reduced intestil permeability in a SH preclinical study
Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 fincial results and to provide operatiol progress updates on April 29, 2019
Mar 19, 2019: Innovate Biopharmaceuticals reports fincing to initiate the first phase 3 clinical trial in celiac disease
Feb 25, 2019: Innovate Biopharmaceuticals announces acceptance of three abstracts focusing on the molecular biology and pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
Dec 17, 2018: Innovate Biopharmaceuticals plans to commence the first ever phase 3 registration trial in celiac disease in 1H 2019 and announce top-line SH data with drug combitions by EASL 2019
Nov 12, 2018: Sanyal Biotechnology and Innovate Biopharmaceuticals present data at AASLD validating a proprietary Leaky Gut assay demonstrating reduced intestil permeability with Larazotide Acetate treatment in a SH preclinical study
Oct 29, 2018: Innovate Biopharmaceuticals announces positive effect of Larazotide Acetate on reducing intestil permeability in a SH preclinical study
May 17, 2018: Celiac Disease KOL and Magement Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2019
Pipeline by Innovate Biopharmacueticals Inc, H2 2019
Pipeline by Oasis Pharmaceuticals LLC, H2 2019
Pipeline by PeptiDream Inc, H2 2019
Pipeline by Sosei Heptares, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019